COVID-19 vaccine boosters from Pfizer Inc PFE / BioNTech SE BNTX and Moderna Inc MRNA become less effective after four months but still provide significant protection against hospitalization, a CDC study found.
- While vaccine efficacy was still strong two months after a booster shot, it declined significantly after four months.
- Efficacy against COVID-19–associated emergency department visits and hospitalization was 87% and 91%, respectively, during the two months after a third dose and decreased to 66% and 78% by the fourth month after a third dose.
- Related: Menstrual Irregularities Cases After mRNA COVID-19 Vaccine - EMA Reviews Cases.
- Protection against hospitalizations exceeded that against emergency department visits.
- Researchers said the results suggest that additional boosters may be needed.
- "The finding that protection conferred by mRNA vaccines waned in the months after receipt of a third vaccine dose reinforces the importance of further consideration of additional doses to sustain or improve protection against COVID-19–associated ED/UC encounters and COVID-19 hospitalizations," CDC wrote.
- Price Action: MRNA shares are down 12.1% at $141.84, PFE stock is down 2.86% at $49.33, and BNTX shares are down 8.59% at $156.27 during the market session on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Posted In: BiotechNewsHealth CareMoversTrading IdeasGeneralBriefsCOVID-19 CoronavirusCOVID-19 Vaccine
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in